Loading…
Loading…
MEDP does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for MEDP and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for MEDP and 80,000+ other tickers.
See exactly how MEDP's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MEDP and 80,000+ other tickers.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes…
Net new business awards reached $873 million in the third quarter. Ending backlog reached $3.2 billion, up 5.6% year over year.
Medpace Holdings, Inc. ( MEDP ) Q3 2026 Earnings Call October 22, 2026 9:00 AM EDT Company Participants David Ruhe - Associate Director of Financial Planning & Analysis August Troendle - CEO, President & Chairman Kevin Brady - CFO & Treasurer Conference Call Participants Michael Cherny - Leerink Partners LLC, Research Division Jailendra Singh - Truist Securities, Inc., Research Division Tucker Remmers - UBS Investment Bank, Research Division Ann Hynes - Mizuho Securities USA LLC, Research Division Justin Bowers - Deutsche Bank AG, Research Division Ryan Halsted - RBC Capital Markets, Research Division David Windley - Jefferies LLC, Research Division Christine Rains - William Blair & Company L.L.C., Research Division Eric Coldwell - Robert W.
Medpace NASDAQ: MEDP reported third-quarter 2026 revenue growth of 8.5% and record net new business awards, while management said the clinical research organization continues to see a strong operating environment marked by healthy request-for-proposal activity, initial award notifications and win rates.
Medpace (MEDP) came out with quarterly earnings of $4.84 per share, beating the Zacks Consensus Estimate of $4.45 per share. This compares to earnings of $3.86 per share a year ago.
On October 21, 2026, Medpace Holdings Inc (MEDP) shares rose 6.4% to $662.48, continuing a strong upward trend that has seen the stock increase 21.4% over the p